About Heat Biologics, Inc.

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

At the moment the company generates 4M USD in revenues.

On its last earning announcement, the company reported a loss of -1.17$ per share.

The book value per share is 1.19$

Heat Biologics, Inc. website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
4M - -16M -376.00% -14M -1.17 - - 12M 1.19 -13M -1M -13M